Your fact-checks will appear here
Organization
Available regulatory and manufacturer materials describe Prevnar 20 (PCV20) as a single-dose adult vaccine that provides "lasting protection" against 20 pneumococcal serotypes and is recommended by AC...
For the 2025–26 U.S. flu season, federal agencies recommend using only single‑dose flu vaccine formulations that are free of the preservative thimerosal; most flu doses already supplied in single‑dose...
The removal of the mercury‑based preservative thimerosal from routine U.S. childhood vaccines began as a precautionary policy action in 1999 and was largely completed for childhood immunizations by 20...
Regulatory agencies and multiple studies since 2021 have linked a very small number of neurological and immune-mediated conditions to the Janssen/Johnson & Johnson (J&J) adenoviral‑vector COVID‑19 vac...
Health authorities kept the core public-health message for 2025–26: everyone aged ≥6 months should get an updated flu vaccine, and the 2025–26 U.S. vaccines were reformulated as trivalent to match cir...
Available reporting and official guidance do not describe the Janssen (Johnson & Johnson) COVID-19 vaccine as a substance the body “expels” on a defined timetable; rather, it is an intramuscular viral...
There are no widely reported, direct drug–drug interactions between COVID‑19 booster vaccines and routine medications; public health agencies and major health outlets instead emphasize safety monitori...
Data from national and international public‑health bodies show COVID‑19 vaccines reduce severe outcomes and deaths, especially in older adults: ACIP/CDC presentations found the 2024–25 vaccines “reduc...
Available reporting and guidance through 2025 shows common COVID-19 vaccine effects are short-lived (injection-site pain, fever, aches) and that large-scale monitoring finds no widespread, previously ...
Available sources show major health authorities do not recommend ivermectin to prevent or treat COVID‑19 and that research has produced mixed, largely negative or low‑quality signals for its effective...
Available sources show that thimerosal — a mercury-containing preservative used historically in multi-dose vaccine vials — was largely phased out of hepatitis B vaccine formulations in the United Stat...
Booster doses of COVID-19 vaccines produce , with most symptoms resolving in 1–3 days; serious events remain rare but vary by age, sex, vaccine type, and dosing interval . Population surveillance and ...
The evidence collected during and after large-scale COVID-19 vaccination campaigns shows different long-term safety signals for the adenovirus-vector Johnson & Johnson (J&J/Janssen) shot versus the mR...
Tetanus is rare in the U.S.; since 2010 there have been fewer than 40 reported cases per year and most cases occur in adults not up to date on tetanus vaccines (CDC surveillance) . Childhood school‑ag...
US immunization guidance has shifted in 2025 from blanket, population-level directives toward more “individual-based decision‑making” for some vaccines: the CDC updated its schedules in October to app...
The Advisory Committee on Immunization Practices (ACIP) and CDC now recommend pneumococcal conjugate vaccine (PCV) use for broader adult groups and retain specific, accelerated schedules for adults wi...
Multiple national immunization schedules were revised for 2025–2026 across high‑ and low‑income settings, driven by new WHO/SAGE guidance, country‑level safety or programmatic data, and updates from a...
Yes — multi-dose vials and thimerosal remain part of the vaccine landscape in 2025, but their use has been sharply narrowed: thimerosal has been removed from most childhood vaccines since the late 199...
The Advisory Committee on Immunization Practices (ACIP) voted 8–3 to remove the long-standing universal newborn hepatitis B (Hep B) birth‑dose recommendation, shifting to individual/shared decision‑ma...
A U.S. policy shift this year has already reclassified how some vaccines — particularly mRNA COVID-19 shots — are recommended: COVID-19 vaccines for 2025–2026 moved to “individual-based decision‑makin...